Isolation, purification and physicochemical properties of the antibiotic complex YA-56, a family of phleomycin-bleomycin group, are described. The antibiotic YA-56 complex was found to be composed mainly of two active components named YA-56X and Y. These components were clearly differentiated from the reported phleomycins and bleomycins by their physicochemical properties. However, by direct comparison, YA-56 X was found to be identical with zorbamycin reported recently. YA-56Y was recognized to be a new antibiotic.
In the course of the screening of new antibiotics, an antibiotic complex named YA-56 belonging to the phleomycin-bleomycin group antibiotics was isolated from the culture filtrate of a streptomyces. The taxonomic studies and the antibiotic production by the YA-56 producing strain, Streptomyces humidus var. antitumoris, were reported in the preceeding paperx).
Antibiotic YA-56was mainly composed of two active components named YA-56 X and Y, of which isolation and characterization have already been communicated briefly2). The present paper deals with the experimental details of the isolation, purification and physicochemical properties of YA-56 X and Y. Examination of chemical constituents of YA-56X and Y achieved through their degradation products will be dealt with in the succeeding paper3). Details of the biological properties of YA-56 X and Y will be reported later. Preparation of YA-56 X and Y YA-56 was recovered from the filtered broth by the procedure outlined in Chart 1. The active principle in the filtrate was first isolated as a bluish powder by an adsorption procedure on a high porous polymer (Duolite S-30) followed by alumina chromatography.
By paper chromatography ( Fig. 3a and 3b YA-56X and Y, as well as their Gu-complexes, were soluble in water, methanol, dimethylformamide and dimethylsulfoxide, slightly soluble in ethanol and insoluble in propanol, butanol, acetone, ethyl acetate, chloroform, benzene, ether, petroleum ether and dioxane.
Comparison of YA-56with Phleomycin, Bleomycin and Zorbamycin From the above-described physicochemical properties (IR, UV, color reactions and the chelating property) and the biological properties, YA-56 X and Y seemed to be related to the previously reported phleomycins5) and bleomycins6).
According to Umezawaet alP the ratio of UVabsorbancies at the two absorption maxima, 244-246 and 295-297 nm, of phleomycin and bleomycin Cu-complexes is of great use in differentiating the members of this family. The ratio reported is 1.1-1.3 in bleomycins, about 2.7-2.8 in phleomycin Dl5 E, G, H and I, and about 1.1-1.3 in phleomycin G,D2 and F. With regard to UV spectra, YA-56 resembles phleomycin Dl5 E, G, H and I, since the ratio is 2.78 in X and 2.8 in Y.
To compare YA-56 with the phleomycin complexes, chromatographic elution patterns on GM-Sephadex columnwere examined according to Ikekawa et alBKAs illustrated in the preliminary communication2), YA-56 X and Y were eluted with 0.2 M ammoniumformate buffer, similarly to phleomycin D^Therefore, YA-56 was à"directly compared with the phleomycin Dt fraction isolated from phleomycin complex by the above-described chromatographic procedure.
As shown in Fig. 3a of YA-56 X and Y from each components of phleomycin and bleomycin was established. This conclusion has been strongly supported by the comparisons of the constituents of these antibiotics, which will be mentioned in the succeeding paper3).
Recently Argoudelis et al.7) reported on production, isolation and characterization of zorbamycin, zorbonomycin B and zorbonomycin C, which were likely new members, of phleomycin-bleomycin group antibiotics. Among these antibiotics, zorbamycin, which gave the UVabsorption curve and the CMSephadex elution pattern of phleomycin Dj type seemed to be similar to YA-56 X. Thus, YA-56 X and Y were compared directly with the authentic sample of zorbamycin, which was kindly afforded by Dr. Argoudelis. As shown in Fig. 3a and 3b , the chromatographic behaviors of YA-56 X and zorbamycin were the same. Moreover, YA-56 X and zorbamycin were not separable by CMSephadex G-25 column chromatography. The NMRspectrum of zorbamycin which was published in the paper7) appeared to be identical with that of YA-56X. As a result, zorbamycin and YA-56X are thought to be identical. Comparative study of the hydrolysates of YA-56 X and zorbamycin, which will be mentioned in the succeeding paper3), supports their identity. YA-56 Y is readily It was quite surprising that zorbamycin (patent name : zorbonomycin) and YA-56 X were independently found and characterized almost at the same time8>9).
Experimental Isolation and Purification
In the course of purification, a cylinder-cup or pulp-disc assay method was applied using Bacillus subtilis PCI 219 and Escherichia coli NIHJ as test organisms. Column chromatographic fractions and the isolated products in all stages of the purification were also monitored by ascending paper chromatography on Toyo No. 51 A paper using solvent system A (BuOH-pyridine-AcOH-H2O, 15: 10:3: 12) and/or solvent system B (0.05M NH4C1, pH 7.5) for development, and using B. subtilis PCI 219 and/or Klebsiella pneumoniae PCI 602 as the test organisms for bioautography. All solvent removals were carried out in vacuo under 40°C.
The fermentation broth was filtered with Celite 545 and adjusted to pH 6.8. The 5 literx3) , and the extract was concentrated to 0.8 liter, to which was added acetone {9 liters) to precipitate a brownish powder (55g). This powder was dissolved in H2O(100 ml) and poured onto a column (8x200cm) of alumina (7.5kg). The column was developed with water and the eluate was fractionated into three portions : the first fraction (Fr. I, 250ml), the second fraction (Fr. II, 1,320ml) and the third fraction (Fr. Ill, 10,730ml).
Fraction II, which was bluish in color and contained main active components, was adjusted to pH 6.4~6.8 and lyophilized to yield a bluish green powder. The powder was extracted with MeOH(125ml) and the extract was concentrated to 50ml. Then, the solution was applied onto a column (5x135cm) of Sephadex LH-20. By developing the column with MeOH, the following three fractions were obtained; the first fraction (Fr. IV, 550ml), the second fraction (Fr. V, 250ml) and the third fraction (Fr. VI, 1,670ml). The main active fraction (Fr. V) was concentrated to 95ml. Acetone was added to this concentrate to yield a blue powder (1.5g). This powder was repeatedly (2~3 times) purified by gel filtration on Sephadex LH-20 using MeOHas a solvent in the manner described above. Separation of YA-56 X and Y Sephadex G-15 (2.4 liters) was boiled in 1N HC1 (2liters) for 2 hours. After cooling, the Sephadex was washed with water until the washed solution showed pH of about 6.2. Then, the Sephadex gel was charged in a column (5x135cm). The hydrochloride of YA-56 Cu-complex (1.78g) was dissolved in 0.2m aqueous NaCl solution and the solution was poured onto the column. By developing the column with the same solvent, YA-56 was observed to be separated into two blue colored bands along the column. Twomain eluates were collected by continuous development with 0.2M aqueous NaCl. The faster moving eluates containing the X component were combined and the solution (245 ml) was lyophilized to give a blue powder (1.12g). precipitate (400 mg), which was further purified by gel filtration of Sephadex LH-20 column in the same manner as described above to yield a purified sample of YA-56Y Cu-complex (78mg).
Preparation of YA-56 X and Y The hydrochloride of YA-56 X Cu-complex (160 mg) was dissolved in dehydrated MeOH (16ml) and dry hydrogen sulfide gas was introduced into the solution at room temperature. The methanolic solution of YA-56 Y Cu-complex (60mg/ml) was treated with hydrogen sulfide in the manner described for YA-56 X. After purification by Sephadex LH-20 gel filtration, the pure sample of YA-56Y (35 mg) was obtained as a white amorphous powder.
